Jasper Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Cost of revenue | $41.6M | $34.3M | — | — | — |
| Research and development | $63.1M | $55.8M | $51.8M | $34.6M | $25.4M |
| Operating expenses | $83.9M | $76.2M | $68.9M | $51.2M | $36.8M |
| Operating income | -$83.9M | -$76.2M | -$68.9M | -$51.2M | -$36.8M |
| Income tax expense | — | $2,000 | $2,000 | — | — |
| Net income | -$75.8M | -$71.3M | -$64.5M | -$37.7M | -$30.6M |
| Balance Sheet | |||||
| Cash and equivalents | $28.7M | $71.6M | $86.9M | $38.2M | $84.7M |
| Current assets | $34.6M | $75.8M | $88.9M | $41.7M | $87.8M |
| Total assets | $35.8M | $79.9M | $94.9M | $48.4M | $93.7M |
| Current liabilities | $13.2M | $15.2M | $12.4M | $7.1M | $8.0M |
| Total liabilities | $31.6M | $18.2M | $16.5M | $12.4M | $24.1M |
| Stockholders' equity | $4.2M | $61.7M | $78.4M | $36.0M | $69.5M |
| Cash Flow Statement | |||||
| Cash from operations | -$77.2M | -$62.6M | -$52.1M | -$45.9M | -$33.7M |
| Depreciation and amortization | $1.1M | $1.4M | $1.1M | $975,000 | $377,000 |
| Stock-based compensation | $6.7M | $6.6M | $5.2M | $4.1M | $1.0M |
Shares outstanding 28.0M · Free float 3.3%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.